Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent
Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial
ETP-ALL May Be Linked To Acute Myeloid Leukemia
CyberKnife Delivers 100 Percent PFS at 18.3 Month Followup
BRCA1 and BRCA2 Mutations Linked To Higher Survival
Matted Lymph Nodes Can Predict Survival Rate, Spread of Disease
Chromosomal Abnormalities Predict Long Median Survival
Analysis Shows No Mortality Benefit From Regular PSA Screening
Ovarian Cancer Symptom Indices May Need to be Re-Evaluated
Self-Collected Pap Smear Tests Could Advance HPV Screening
Trials Approved by NCI CTEP For the Month of January
Palmetto Establishes Coverage For Thyroid Genomic Test
FDA Approves Inlyta Pill For Renal Cell Carcinoma
Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Jonathan Licht named president, chief scientific officer at Van Andel Institute
- Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies - Duke brain cancer researcher Kyle Walsh named director of NIEHS
